Sign in
Taking people in United StatesNo phase

Blood Test Study for Men With High-Risk Localized Prostate Cancer

Collects blood samples from adults with high-risk localized prostate cancer before surgery.

Key facts

Who runs it
University of Pittsburgh
Where
Pittsburgh, United StatesSee the site
Trial code
Registry title
Circulating Tumor DNA in High Risk Localized Prostate Cancer
Status
Recruiting
People taking part
24 people, planned
Started
23 Sept 2025
Expected to end
30 Sept 2027
Type of study
Observational
Record updated
9 November 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for men with prostate cancer who are willing to give blood and tumor tissue samples. The main group has high-risk cancer that has not spread far and is planned for prostate surgery.

Age
18 years or older
Sex
Men only
Disease stage
Main group: high-risk localized prostate adenocarcinoma, defined as clinical stage cT3a or higher, Grade Group 4 or 5 (Gleason sum 8-10), and PSA 20 or higher. A second exploratory group includes men on active surveillance, men whose PSA rose after local treatment, men with hormone-sensitive metastatic cancer, and men with metastatic CRPC.
Earlier treatment
People receiving androgen deprivation or other systemic therapy for prostate cancer cannot join.
Biomarker or test result
No gene or marker result is required. People must be willing to give serial blood samples and tumor tissue for comparison with circulating tumor DNA (ctDNA).

Main reasons for not taking part

  • Another primary cancer in the last 3 years, except non-melanomatous skin cancer
  • Receiving androgen deprivation or other systemic therapy for prostate cancer
  • A medical or social situation that could prevent following the study plan

The registry criteria, word for word

Show all 11 criteriaShow less

Who can take part

  • Must have histologically confirmed prostate cancer
  • Age ≥ 18 years
  • ECOG performance status of 0-1
  • Must have the ability to understand and the willingness to sign a written informed consent document
  • Willing to provide serial blood samples for the study
  • Willing to provide tumor tissue (prostatectomy for primary cohort; prostatectomy or biopsy for exploratory cohort) for correlative studies which will compare ctDNA to tumor specimens
  • Primary Cohort: High-risk localized prostate adenocarcinoma defined as one or more of the following:; o Clinical stage ≥ cT3a, Grade Group 4 or 5 (Gleason sum 8-10), and PSA ≥ 20; *Non-bulky pelvic lymphadenopathy and indeterminate findings on staging imaging (CT, bone scan, PSMA PET CT) are allowed if the surgeon believes RP is appropriate
  • Exploratory Cohort: Men with a diagnosis of prostate adenocarcinoma and one of the following:; Localized prostate adenocarcinoma on active surveillance; Biochemically-recurrent prostate adenocarcinoma after definitive local therapy; Hormone-sensitive, metastatic prostate adenocarcinoma; Metastatic CRPC

Who cannot take part

  • Receiving androgen deprivation or other systemic therapy for prostate cancer
  • History of another primary cancer within the last 3 years, except for non-melanomatous skin cancer
  • Medical condition or social situation that may preclude adherence to the protocol; -

Where in United States

  • UPMC Hillman Cancer CenterPittsburgh, United StatesContact: Brieanna Marino, MSTaking people

About the trial

What the trial wants to find out

This prospective, non-therapeutic translational biomarker study will collect blood in patients with high risk localized prostate cancer prior to prostatectomy.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Circulating Tumor DNA in High Risk Localized Prostate Cancer
Plain-language title
Blood Test Study for Men With High-Risk Localized Prostate CancerGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
9 November 2026